Zacks: Brokerages Expect Histogenics Corporation (HSGX) Will Announce Earnings of -$0.30 Per Share
Equities analysts expect that Histogenics Corporation (NASDAQ:HSGX) will announce earnings per share of ($0.30) for the current quarter, Zacks reports. Zero analysts have issued estimates for Histogenics Corporation’s earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.31). Histogenics Corporation reported earnings of ($0.51) per share in the same quarter last year, which would indicate a positive year over year growth rate of 41.2%. The firm is expected to announce its next earnings report before the market opens on Thursday, November 9th.
On average, analysts expect that Histogenics Corporation will report full year earnings of ($1.09) per share for the current year, with EPS estimates ranging from ($1.18) to ($0.99). For the next year, analysts forecast that the business will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.68) to ($0.50). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Histogenics Corporation.
Histogenics Corporation (NASDAQ:HSGX) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. During the same quarter in the previous year, the firm earned ($0.61) EPS.
HSGX has been the subject of a number of research analyst reports. HC Wainwright set a $4.00 target price on Histogenics Corporation and gave the company a “buy” rating in a research report on Friday, August 11th. Canaccord Genuity reaffirmed a “buy” rating and set a $4.00 target price on shares of Histogenics Corporation in a research report on Friday, August 11th. Zacks Investment Research raised Histogenics Corporation from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research report on Tuesday, August 15th. Finally, ValuEngine raised Histogenics Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd.
Shares of Histogenics Corporation (NASDAQ HSGX) traded up 2.84% during mid-day trading on Thursday, reaching $2.18. 193,831 shares of the company were exchanged. The company’s market capitalization is $49.03 million. Histogenics Corporation has a 12 month low of $1.45 and a 12 month high of $3.00. The firm’s 50-day moving average is $2.04 and its 200-day moving average is $1.82.
TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/19/zacks-brokerages-expect-histogenics-corporation-hsgx-will-announce-earnings-of-0-30-per-share.html.
Histogenics Corporation Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.